Lower fracture risk in older men with higher sclerostin concentration: A prospective analysis from the MINOS study

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 855-864

  Szulc, Pawel ^a   Bertholon, Cindy ^a   Borel, Olivier ^a   Marchand, Francois ^b   Chapurlat, Roland ^a  

^a UNIVERSITÉ DE LYON   (France)

^b Caisse Regionale Miniere (Previously SSMB)   (France)

Author keywords

bone mineral density; fracture; men; osteoporosis; sclerostin

Indexed keywords

ESTRADIOL; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ABDOMINAL AORTA; ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY WEIGHT; BONE MINERAL; BONE TURNOVER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FALLING; FOLLOW UP; FOREARM; FRACTURE; FRAGILITY FRACTURE; HAZARD RATIO; HIP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LEISURE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHYSICAL ACTIVITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; BLOOD; BONE; BONE DENSITY; FRACTURES, BONE; FRANCE; GENETIC MARKER; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FOLLOW-UP STUDIES; FRACTURES, BONE; FRANCE; GENETIC MARKERS; HUMANS; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84875186616     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1823     Document Type: Article

References (51)

1. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA., Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34: 195-202.
2. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD., Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporos Int. 2005; 16: 1184-92.
3. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD., Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005; 20: 1813-9.
4. Haentjens P, Johnell O, Kanis JA, Bouillon R, Cooper C, Lamraski G, Vanderschueren D, Kaufman JM, Boonen S., Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res. 2004; 19: 1933-44.
5. Blaizot S, Delmas PD, Marchand F, Chapurlat R, Szulc P., Risk factors for peripheral fractures vary by age in older men-the prospective MINOS study. Osteoporos Int. 2011; 22: 1755-64.
6. Wang TK, Bolland MJ, van Pelt NC, Horne AM, Mason BH, Ames RW, Grey AB, Ruygrok PN, Gamble GD, Reid IR., Relationships between vascular calcification, calcium metabolism, bone density, and fractures. J Bone Miner Res. 2010; 25: 2777-85.
7. Szulc P, Montella A, Delmas PD., High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study. Ann Rheum Dis. 2008; 67: 1249-55.
8. Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E., Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res. 2009; 24: 2032-8.
9. Bauer DC, Ewing SK, Cauley JA, Ensrud KE, Cummings SR., Orwoll ES Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study. Osteoporos Int. 2007; 18: 771-7.
10. Black DM, Bouxsein ML, Marshall LM, Cummings SR, Lang TF, Cauley JA, Ensrud KE, Nielson CM, Orwoll ES., Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res. 2008; 23: 1326-33.
11. Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL., Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87: 99-107.
12. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH., Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011; 26: 2812-22.
13. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A., Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012; 97: 148-54.
14. Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J, Liao E., Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women. Clin Endocrinol. 2012; 76: 797-801.
15. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S., Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011; 26: 373-9.
16. Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M., Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012; 27: 226-30.
17. Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR., Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012; 97: 2027-32.
18. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA., High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the CEOR study. J Bone Miner Res. 2012; 26: 2592-2602.
19. Szulc P, Marchand F, Duboeuf F, Delmas PD., Cross-sectional assessment of age-related bone loss in men. Bone. 2000; 26: 123-9.
20. Szulc P, Maurice C, Marchand F, Delmas PD., Increased bone resorption is associated with higher mortality in community-dwelling men >or = 50 years of age: the MINOS study. J Bone Miner Res. 2009; 24: 1116-24.
21. Szulc P, Samelson EJ, Kiel DP, Delmas PD., Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study. J Bone Miner Res. 2009; 24: 2023-31.
22. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD., Low width of tubular bones is associated with increased risk of fragility fracture in elderly men-the MINOS study. Bone. 2006; 38: 595-602.
23. Mc Nulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R., Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. Clin Endocrinol Metab. 2011; 96: E1159-62.
24. Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD., Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res. 2001; 16: 1642-50.
25. Szulc P, Uusi-Rasi K, Claustrat B, Marchand F, Beck TJ, Delmas PD., Role of sex steroids in the regulation of bone morphology in men. The MINOS study. Osteoporos Int. 2004; 15: 909-17.
26. Vermeulen A, Verdonck L, Kaufman JM., A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84: 3666-72.
27. Szulc P, Claustrat B, Munoz F, Marchand F, Delmas PD., Assessment of the role of 17beta-oestradiol in bone metabolism in men: does the assay technique matter? The MINOS study. Clin Endocrinol. 2004; 61: 447-57.
28. Szulc P, Munoz F, Marchand F, Chapuy MC, Delmas PD., Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study. Calcif Tissue Int. 2003; 73: 520-30.
29. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J., A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-12.
30. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW., New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997; 132: 245-50.
31. Szulc P, Kiel DP, Delmas PD., Calcifications in the abdominal aorta predict fractures in men: MINOS study. J Bone Miner Res. 2008; 23: 95-102.
32. Szulc P, Delmas PD., Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008; 19: 1683-704.
33. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S., Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011; 26: 27-34.
34. Szulc P, Boutroy S, Vilayphiou N, Chaitou A, Delmas PD, Chapurlat R., Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: the STRAMBO study. J Bone Miner Res. 2011; 26: 1358-67.
35. Cauley JA, Blackwell T, Zmuda JM, Fullman RL, Ensrud KE, Stone KL, Barrett-Connor E, Orwoll ES., Correlates of trabecular and cortical volumetric bone mineral density at the femoral neck and lumbar spine: the osteoporotic fractures in men study (MrOS). J Bone Miner Res. 2010; 25: 1958-71.
36. Sheu Y, Zmuda JM, Boudreau RM, Petit MA, Ensrud KE, Bauer DC, Gordon CL, Orwoll ES, Cauley JA., Bone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2011; 26: 63-71.
37. Delgado-Calle J, Arozamena J, García-Renedo R, García-Ibarbia C, Pascual-Carra MA, González-Macías J, Riancho JA., Osteocyte deficiency in hip fractures. Calcif Tissue Int. 2011; 89: 327-34.
38. Power J, Doube M, van Bezooijen RL, Loveridge N, Reeve J., Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck. Bone. 2012; 50: 1107-14.
39. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH., Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283: 5866-75.
40. Moustafa A, Sugiyama T, Prasad J, Zaman G, Gross TS, Lanyon LE, Price JS., Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int. 2012; 23: 1225-34.
41. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE., Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95: 2248-53.
42. Spatz JM, Fields EE, Yu EW, Pajevic PD, Bouxsein ML, Sibonga JD, Zwart SR, Smith SM., Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012; 97: E1736-40.
43. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22: 6267-76.
44. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ., Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011; 6: e25900.
45. Padhi D, Jang G, Stouch B, Fang L, Posvar E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19-26.
46. Chaitou A, Boutroy S, Vilayphiou N, Munoz F, Delmas PD, Chapurlat R, Szulc P., Association between bone turnover rate and bone microarchitecture in men: the STRAMBO study. J Bone Miner Res. 2010; 25: 2313-23.
47. Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alías AM, Lowik C, Papapoulos S, Reeve J, Loveridge N., Sclerostin and the regulation of bone formation: effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res. 2010; 25: 1867-76.
48. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M., Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone. 2012; 50: 739-42.
49. Adami S, Gatti D, Bertoldo F, Sartori L, Di Munno O, Filipponi P, Marcocci C, Frediani B, Palummeri E, Fiore CE, Costi D, Rossini M., Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif Tissue Int. 2008; 83: 301-7.
50. Chung YE, Lee SH, Lee SY, Kim SY, Kim HH, Mirza FS, Lee SK, Lorenzo JA, Kim GS, Koh JM., Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int. 2012; 23: 1235-43.
51. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD., Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009; 284: 10890-900.